Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

News Daily News

Year in Review: Evidence Around AI in Cardiology Grows

Todd Neale

December 23, 2025

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

FDA Approves TriClip TEER Device for Tricuspid Repair

L.A. McKeown

April 02, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2024

Shelley Wood

March 01, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2023

Caitlin E. Cox

September 04, 2023

News Daily News

Testosterone Doesn’t Cause CV Events in High-Risk Men With Hypogonadism

Caitlin E. Cox

June 16, 2023

News Opinion CV Team Dispatch

June 2022 News Roundup

L.A. McKeown

June 01, 2022

News Daily News

Could an App Replace Statin Prescribing by Doctors?

Michael O'Riordan

September 08, 2021

News Features

As US Cardiologists Mull a Biden Presidency, COVID-19 Trumps All

Todd Neale

November 13, 2020

News Conference News STS 2020

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

Yael L. Maxwell

January 29, 2020

News Daily News

Implantable Cardiac Monitor May Reduce Delays to Hospital in High-Risk ACS

L.A. McKeown

October 15, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News CRT 2019

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

Yael L. Maxwell

March 03, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

Michael O'Riordan

May 08, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

Advertisement

Year in Review: Evidence Around AI in Cardiology Grows

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

FDA Approves TriClip TEER Device for Tricuspid Repair

TCTMD’s Top 10 Most Popular Stories for February 2024

TCTMD’s Top 10 Most Popular Stories for August 2023

Testosterone Doesn’t Cause CV Events in High-Risk Men With Hypogonadism

June 2022 News Roundup

Could an App Replace Statin Prescribing by Doctors?

As US Cardiologists Mull a Biden Presidency, COVID-19 Trumps All

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

Implantable Cardiac Monitor May Reduce Delays to Hospital in High-Risk ACS

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content